
Overview
As instructor of oncology and pediatrics, Llosa’s research focus is the immunotherapy of sarcomas. My research focuses on understanding how the immune system interacts with cancer cells from sarcoma tumors. Sarcoma is a type of cancer that can occur in various locations in the body. Sarcoma is the general term for a broad group of cancers that includes tumors that form in the bones and in the soft (also called connective) tissues. Sarcomas affect people of all ages and some, such as Rhabdomyosarcoma, Neuroblastoma, Ewings sarcoma and Osteosarcoma, are more common in children and young adults. Treatments for sarcoma vary depending on tumor type, location and other factors. I concentrate in the immunotherapy of sarcomas. Immunotherapy (also called biologic therapy or biotherapy) is a type of cancer treatment designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. Immunotherapy works by stopping or slowing the growth of cancer cells, stopping cancer from spreading to other parts of the body, or helping the immune system increase its effectiveness at eliminating cancer cells. There are several types of immunotherapy, including monoclonal antibodies, non-specific immunotherapies, and cancer vaccines. My specific area of interest is the use of drugs that target immune system checkpoints. The immune system has checkpoints to keep itself from attacking other normal cells in the body. Cancer cells sometimes take advantage of these checkpoints to avoid being attacked by the immune system. CTLA-4 and PD-1/PD-L1 are checkpoint molecules found on immune system cells (T cells) that can be blocked with drugs leading to a general raise in the immune system of the patients which helps it attack cancer cells. These types of drugs are currently being given to patients with melanoma (skin cancer), lung cancer and kidney cancer with great success and they have been found to shrink advanced tumors in many people. The best part of the treatment is that many of these tumor responses have been long-lasting so far, and the side effects are generally less serious than when using chemotherapy. Larger clinical trials are now studying both drugs, both alone and/or in combination with other treatments. My task is and will continue to be using the same type of approach for attacking sarcomas and hopefully obtained the very promising results and long lasting responses observed with the use of immune checkpoint inhibitors in other types of cancer.
Dr. Llosa is highly rated in 5 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Malignant Peripheral Nerve Sheath Tumor, Rhabdomyosarcoma, and Bone Marrow Transplant.
His clinical research consists of co-authoring 43 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.
Residency
Specialties
Licenses
Board Certifications
Fellowships
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- EPO
- HMO
- POS
- PPO
Locations
1800 Orleans Street, Bloomberg 11N, Bloomberg 11N, Baltimore, MD 21287
Additional Areas of Focus
Dr. Llosa has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
2 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is highly rated in 19 conditions, according to our data. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.
Office
Taofeek Owonikoko is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.
Sidney Kimmel Comprehensive Cancer Center
Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is highly rated in 22 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Frequently Asked Questions about Dr. Nicolas Llosa
How do I make an appointment with Dr. Nicolas Llosa?
You can book an appointment with Dr. Nicolas Llosa by calling their office at 410-955-8751. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Nicolas Llosa a top-rated expert for Adult Soft Tissue Sarcoma?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nicolas Llosa is classified as an Advanced expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Nicolas Llosa specialize in?
While Dr. Nicolas Llosa is a Oncology, they have specific expertise in Adult Soft Tissue Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.
Does Dr. Nicolas Llosa participate in research or clinical trials?
Yes. Dr. Nicolas Llosa has published 43 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Dr. Nicolas Llosa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Nicolas Llosa accept my insurance?
Dr. Nicolas Llosa accepts most major insurance plans, including Aetna and CareFirst. We recommend calling the office directly at 410-955-8751 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Adult Soft Tissue SarcomaDr. Llosa isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- Ewing SarcomaDr. Llosa isAdvanced. Learn about Ewing Sarcoma.
- Malignant Peripheral Nerve Sheath Tumor
- OsteosarcomaDr. Llosa isAdvanced. Learn about Osteosarcoma.
- RhabdomyosarcomaDr. Llosa isAdvanced. Learn about Rhabdomyosarcoma.
- Experienced
- Bone Marrow TransplantDr. Llosa isExperienced. Learn about Bone Marrow Transplant.
- Graft Versus Host Disease (GvHD)Dr. Llosa isExperienced. Learn about Graft Versus Host Disease (GvHD).
- Neurofibromatosis Type 1 (NF1)Dr. Llosa isExperienced. Learn about Neurofibromatosis Type 1 (NF1).

